Searched for
PRICE DROP SEMAGLUTIDE
India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Weight-loss drug semaglutide set to get cheaper as generic wave builds in IndiaPrices for generic semaglutide, a popular weight-loss drug, are expected to fall by more than half in the coming months. This sharp decline...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- A blockbuster unleashed: What happens when a big fat business explodes?India is set to experience a dramatic shift as Ozempic and Wegovy's active ingredient, semaglutide, becomes widely available. Over 40 India...
- The weight is over. This injectable fits the billIndia's diabetes and weight-loss drug market is set for a major shift. Novo Nordisk's popular drug semaglutide is now off patent. Over 40 c...
- Mankind Pharma targets early Semaglutide launchMankind Pharma is set to enter India's semaglutide market soon. The drug's patent expires this month, opening doors for new players. Mankin...
- Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal against Eli Lilly’s TirzepatideNVO stock today: Novo Nordisk shares plummeted after its next-generation weight loss drug, CagriSema, failed to achieve non-inferiority in ...
- Table 2.0: Restaurants absorb 'Ozempic effect' for weight-loss drug consumersIndian restaurants are adapting to a growing consumer base using weight-loss medications like Ozempic and Mounjaro by introducing "Size O" ...
- Novo Nordisk says Alzheimer's drug trial fails to meet main goalNovo Nordisk's Alzheimer's drug trials have ended without success. The semaglutide pill did not slow the brain disease's progression. This ...
- Novo Nordisk Stock Share Price Today: Why company's shares are down? Here's Alzheimer drug’s trial outcome, stock market impact, analysts insightsNovo Nordisk stock share price today fell after the company announced that semaglutide, used in Ozempic and Wegovy, failed to slow Alzheime...
- Sensex slips over 500 pts, Nifty breaks below 26,900 as Fed signals rate-cut pauseOn Thursday, Indian stock markets began the day on a sour note, with both the Sensex and Nifty taking a dip in response to international ma...
- Buy, Sell or Hold: Elara recommends buy on Dr Reddy’s Laboratories; Goldman raises target on Varun BeveragesBrokerages remain positive on select large and mid-cap stocks, including Dr. Reddy’s, Coal India, and Varun Beverages, citing strong earnin...
- IMA warns of misuse, mis-prescription of new weight-loss drugs, such as Wegovy and MounjaroThe Indian Medical Association is raising concerns about the misuse of weight-loss drugs like Wegovy and Mounjaro, urging stricter prescrip...
- Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming weight-loss dr...
- Hims stock tanks over 20% after Wegovy deal collapse — why Novo Nordisk’s breakup over weight loss drugs is shaking up Wall StreetHims stock took a major hit after Novo Nordisk suddenly ended their Wegovy partnership, causing shares to drop over 20% in a single day. Th...
- Indian pharma cos to launch cheaper diabetes medicine at 90% lower price soonDomestic drug companies in India are preparing to launch affordable generics of the diabetes drug Empagliflozin after the expiry of Boehrin...
Load More
